2. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.
3. Dubertret L. Psoriasis from clinic to therapy 2005;1st ed. Paris: Medcom. 61-65.
4. Seville RH. Advances in the use of anthralin. J Am Acad Dermatol 1981;5:319-321.
5. Montes LF, Wilborn WH, Brody I. Low strength anthralin in Psoriasis. J Cutan Pathol 1979;6:445-456.
6. Farber EM, Abel EA, Charuworn A. Recent advances in the treatment of psoriasis. J Am Acad Dermatol 1983;8:311-321.
7. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol 2001;2:95-120.
8. Park SB, Suh DH, Youn JI. A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol 1999;16:321-325.
9. Langner A, Verjans H, Sfapor V, Molt M. 1α, 25-dihydroxy vitamin D3 (Clcitriol) ointment in psoriasis. J Dermatol Treat 1992;3:177-180.
11. Marks R. The role of tazarotene in the treatment of psoriasis. Brit J Dermatol 1999;140:Suppl. 24-28.
12. LeVine MJ, White HA, Parrish JA. Components of the Goeckerman regimen. J Invest Dermatol 1979;73:170-173.
13. Ingram JT. The approach to psoriasis. Br Med J 1953;2:591-594.
14. LeVine MJ, Parrish JA. Outpatient phototherapy of psoriasis. Arch Dermatol 1980;116:552-554.
15. Parrish JA, Fitzapatrick TB, Tannenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. New Eng J Med 1974;291:1207-1211.
16. British Photodermatology Group guidelines for PUVA. Br J Dermatol 1994;130:246-255.
17. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988;91:120-124.
18. Parrish JA, Jaenicke KF. Action spectrum for phototherapy of psoriasis. J Invest Dermatol 1981;76:359-362.
19. Van Weelden H, Faille B, Young E, Van der Leun JC. A new development in UVB phototherapy of psoriasis. Brit J Dermatol 1988;119:11-19.
20. Walters IB, Burack LH, Coven TR, Gilleaudean P, Krueger G. Suberythemogenic narrow band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999;40:893-900.
21. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24:591-594.
22. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998;39:464-475.
23. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. systemic therapies. J Am Acad Dermatol 2001;45:649-661.
24. Roenigk HH Jr, Maibach HI, Weinstein GD. Guidelines on methotrexate therapy for psoriasis. Arch Dermatol 1972;105:363-365.
25. Roenigk HH Jr, Maibach HI, Weinstein GD. Methotrexate therapy for psoriasis: guideline revisions. Arch Dermatol 1973;108:36-42.
26. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate guidelines-revised. J Am Acad Dermatol 1982;6:145-155.
27. Sterry W, Barker J, Boehncke WH, Boss JD, Chimenti S, Voorhees . Biological therapy in the systemic managements of psoriasis: International consensus conference. Brit J Dermatol 2004;151:3-17.
28. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CEM. An international, randomized, double blind, placebo controlled phase 3 trial of intramuscular alephacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-727.
29. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldmann SR, Gottlieb AB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425-433.
30. Goffe B, Cather JC. Etanercept : An overview. J Am Acad Dermatol 2003;49:S105-S111.
31. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque type psoriasis: a randomised trial. Lancet 2001;357:1842-1847.